Analysts Set Nektar Therapeutics (NASDAQ:NKTR) Target Price at $4.92

Shares of Nektar Therapeutics (NASDAQ:NKTR) have earned a consensus recommendation of “Buy” from the seven brokerages that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $4.92.

Several research firms have commented on NKTR. William Blair restated a “market perform” rating on shares of Nektar Therapeutics in a report on Thursday, March 13th. B. Riley assumed coverage on shares of Nektar Therapeutics in a research report on Wednesday, January 8th. They set a “buy” rating and a $4.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and set a $6.50 price target on shares of Nektar Therapeutics in a research note on Thursday, March 13th. Finally, Oppenheimer raised shares of Nektar Therapeutics from a “market perform” rating to an “outperform” rating and set a $6.00 price objective for the company in a research note on Friday, March 14th.

Institutional Investors Weigh In On Nektar Therapeutics

Several institutional investors have recently bought and sold shares of NKTR. Two Sigma Securities LLC raised its stake in shares of Nektar Therapeutics by 56.3% in the 4th quarter. Two Sigma Securities LLC now owns 27,654 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 9,958 shares during the period. Harvest Investment Services LLC purchased a new position in Nektar Therapeutics in the fourth quarter valued at about $27,000. US Asset Management LLC purchased a new position in Nektar Therapeutics in the fourth quarter valued at about $31,000. Intech Investment Management LLC acquired a new position in shares of Nektar Therapeutics during the third quarter worth about $41,000. Finally, XTX Topco Ltd purchased a new stake in shares of Nektar Therapeutics in the third quarter worth about $46,000. 75.88% of the stock is currently owned by hedge funds and other institutional investors.

Nektar Therapeutics Stock Performance

Shares of NASDAQ NKTR opened at $0.55 on Friday. The firm has a market cap of $102.71 million, a P/E ratio of -0.66 and a beta of 0.69. Nektar Therapeutics has a 1 year low of $0.53 and a 1 year high of $1.93. The firm’s 50 day moving average price is $0.82 and its 200 day moving average price is $1.03.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings data on Wednesday, March 12th. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.33. The business had revenue of $29.18 million for the quarter, compared to analysts’ expectations of $36.65 million. Nektar Therapeutics had a negative return on equity of 173.28% and a negative net margin of 180.70%. As a group, equities analysts predict that Nektar Therapeutics will post -0.72 EPS for the current year.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.